Sign in
CompletedNo phase

BRAINI-2 Elderly Mild TBI European Study

Key facts

Who runs it
Hospital Universitario 12 de Octubre
Where
France, Germany, and Spain7 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
2,297 people enrolled
Started
1 Mar 2022
Ended
30 Mar 2025
Type of study
Observational, 2 groups
Treatments tested
  • GFAP and UCH-L1
Record updated
29 December 2025

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • BRAINI2-ELDERLY DIAGNOSTIC \& PROGNOSTIC:; Patients ≥65 years of age; Mild TBI (GCS 13-15 on admission) with indication of brain CT scan in the 12 hours after injury ; Blood sample obtained ≤12 h after injury and CT scan preferably ≤6h from blood sample
  • BRAINI2-ELDERLY REFERENCE:; Non TBI patients ≥65 years of age

Who cannot take part

  • BRAINI2-ELDERLY REFERENCE:; Subject in inclusion period of another drug interventional study; Patients harboring a brain tumor; Patients that have had a stroke or neurosurgical operation 1 month prior to the inclusion in the study
  • BRAINI2-ELDERLY DIAGNOSTIC \& PROGNOSTIC:; Age below 65 years; GCS 3-12 on admission; Time of injury unknown; Time to injury exceeding 12 hours; Primary admission for non-traumatic neurological disorder (e.g., stroke, spontaneous, intracranial hematoma); Penetrating head trauma; Patient with mechanical ventilation from the trauma scene or prehospital management; Venipuncture not feasible; No realization of brain CT-scan; Subject under judiciary control; Subject in inclusion period of a drug interventional study

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Mild traumatic brain injury (mTBI) is one of the most frequent emergencies in the elderly population. Despite most mTBI are managed with cranial computed tomography (CT), only 10% of CTs show lesions, determining CT overuse. The use of serum glial fibrillary acidic protein (GFAP) and Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) have shown potential for ruling out the need for cranial CT. However evidence on biomarker use in mild TBI were not based on studies that included aged participants and patients with comorbidities for which biomarker levels could vary. This is why there is a need for a prospective study that assesses the predictive performance of these two biomarkers in the elderly population, both in elderly patients suffering mild TBI and in a reference population, including patients and participants with and without comorbidities.

The 2 groups in the trial

  • BRAINI2-ELDERLY DIAGNOSTIC & PROGNOSTIC

    2370 patients suffering mild Traumatic brain injury

    Treatment: GFAP and UCH-L1

  • BRAINI2-ELDERLY REFERENCE

    480 non-tbi elderly reference patients

    Treatment: GFAP and UCH-L1

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Blood Biomarkers to Improve Management of Mild Traumatic BRAIN Injury in the Elderly
Publications
Record updated
29 December 2025